Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of HDAC4 substantially promoted the expression of CDK1 and CDK2 and vimentin in glioma U251 cells.
|
30272277 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, the mechanism of HOTTIP-mediated reduction of glioma cell growth may involve the suppression of cyclin A and CDK2 protein expression, which increases P53 protein expression via the down-regulation of BRE.
|
27733185 |
2016 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings show that CDKN2 p16 540 C>G, CDKN2 p16 580 C>T and MDM2 SNP309 T>G variants and their haplotypes may be risk factors for the development of primary brain tumors, especially of glioma.
|
26124340 |
2015 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCRK expression was knocked down in human glioma U-373 MG and U-87 MG cells with small-interfering RNAs and short hairpin RNAs (siCCRK and shCCRK, respectively), and cell proliferation, cell cycle distribution, and cyclin-dependent kinase 2 (CDK2) phosphorylation were examined.
|
17565152 |
2007 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular analysis of CDKN2 (p16) in gliomas associated with clinical data.
|
11496313 |
2001 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The occurrence of p16/CDKN2 germline mutations in 12 Icelandic melanoma kindreds (kindreds with two or more cases of melanoma or melanoma, pancreas and/or glioma cases) was examined.
|
10651484 |
1998 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro.
|
9366522 |
1997 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have analysed the significance of the loss of this gene in gliomas by introducing the cDNA for p16INK4A into the human glioma cell line U-1242 MG which has a deleted CDKN2 locus.
|
9247304 |
1997 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that p16/CDKN2 inactivation is a significant factor in the genesis and progression of gliomas and that the restoration of the wild-type p16 protein could have clinical and therapeutic utility.
|
8552379 |
1996 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings also provide corroborative evidence that CDKN2/p16 and RB are the critical glioma tumor suppressor genes on chromosomes 9p and 13q, respectively.
|
8548755 |
1996 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
|
7867008 |
1995 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest: (a) the involvement of P16INK4 in glioma progression; (b) that mechanisms other than mutation or deletion can down-regulate expression of the p16/CDKN2 gene; and (c) that the balance between CDK4 and its cognate inhibitor, P16INK4, may confer a cell growth advantage and facilitate tumor progression.
|
7728764 |
1995 |